vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and MFA FINANCIAL, INC. (MFA). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $55.5M, roughly 1.1× MFA FINANCIAL, INC.). On growth, MFA FINANCIAL, INC. posted the faster year-over-year revenue change (9.2% vs 8.1%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 7.7%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
MFA Financial, Inc. is a U.S.-headquartered real estate investment trust (REIT) specializing in investing in and managing residential and commercial mortgage-backed securities, mortgage loans, and other real estate-related financial assets. It caters primarily to institutional and individual investors across the U.S., focusing on delivering stable risk-adjusted returns via rigorous asset screening and risk management frameworks.
CTKB vs MFA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $55.5M |
| Net Profit | $-44.1M | — |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 97.9% |
| Net Margin | -70.9% | — |
| Revenue YoY | 8.1% | 9.2% |
| Net Profit YoY | -557.1% | — |
| EPS (diluted) | — | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $55.5M | ||
| Q3 25 | $52.3M | $56.8M | ||
| Q2 25 | $45.6M | $61.3M | ||
| Q1 25 | $41.5M | $57.5M | ||
| Q4 24 | $57.5M | $50.8M | ||
| Q3 24 | $51.5M | $50.6M | ||
| Q2 24 | $46.6M | $53.5M | ||
| Q1 24 | $44.9M | $47.8M |
| Q4 25 | $-44.1M | — | ||
| Q3 25 | $-5.5M | $48.1M | ||
| Q2 25 | $-5.6M | $33.2M | ||
| Q1 25 | $-11.4M | $41.2M | ||
| Q4 24 | $9.6M | — | ||
| Q3 24 | $941.0K | $48.2M | ||
| Q2 24 | $-10.4M | $41.9M | ||
| Q1 24 | $-6.2M | $23.2M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | 97.9% | ||
| Q3 25 | -17.6% | 84.5% | ||
| Q2 25 | -23.3% | 54.5% | ||
| Q1 25 | -36.1% | 70.0% | ||
| Q4 24 | 5.2% | 6.8% | ||
| Q3 24 | -8.2% | 98.2% | ||
| Q2 24 | -18.3% | 79.1% | ||
| Q1 24 | -23.9% | 50.7% |
| Q4 25 | -70.9% | — | ||
| Q3 25 | -10.5% | 84.7% | ||
| Q2 25 | -12.2% | 54.2% | ||
| Q1 25 | -27.5% | 71.6% | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 1.8% | 95.2% | ||
| Q2 24 | -22.4% | 78.4% | ||
| Q1 24 | -13.8% | 48.5% |
| Q4 25 | — | $0.43 | ||
| Q3 25 | — | $0.35 | ||
| Q2 25 | — | $0.21 | ||
| Q1 25 | — | $0.31 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $0.37 | ||
| Q2 24 | — | $0.32 | ||
| Q1 24 | — | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $213.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $1.8B |
| Total Assets | $461.5M | $13.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $213.2M | ||
| Q3 25 | $93.3M | $305.2M | ||
| Q2 25 | $75.5M | $275.7M | ||
| Q1 25 | $95.3M | $253.7M | ||
| Q4 24 | $98.7M | $338.9M | ||
| Q3 24 | $162.3M | $305.6M | ||
| Q2 24 | $177.9M | $289.4M | ||
| Q1 24 | $168.8M | $306.3M |
| Q4 25 | $341.7M | $1.8B | ||
| Q3 25 | $378.6M | $1.8B | ||
| Q2 25 | $377.6M | $1.8B | ||
| Q1 25 | $379.6M | $1.8B | ||
| Q4 24 | $395.7M | $1.8B | ||
| Q3 24 | $385.5M | $1.9B | ||
| Q2 24 | $389.1M | $1.9B | ||
| Q1 24 | $392.6M | $1.9B |
| Q4 25 | $461.5M | $13.0B | ||
| Q3 25 | $494.9M | $12.1B | ||
| Q2 25 | $493.3M | $11.7B | ||
| Q1 25 | $482.6M | $11.5B | ||
| Q4 24 | $499.5M | $11.4B | ||
| Q3 24 | $491.2M | $11.2B | ||
| Q2 24 | $483.7M | $11.1B | ||
| Q1 24 | $492.1M | $10.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $76.2M |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $76.2M | ||
| Q3 25 | $-3.9M | $14.7M | ||
| Q2 25 | $108.0K | $38.5M | ||
| Q1 25 | $-125.0K | $-14.6M | ||
| Q4 24 | $2.0M | $200.1M | ||
| Q3 24 | $13.2M | $-11.3M | ||
| Q2 24 | $6.2M | $46.5M | ||
| Q1 24 | $4.0M | $53.5M |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $3.4M | — |
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | -0.35× | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | -0.23× | ||
| Q2 24 | — | 1.11× | ||
| Q1 24 | — | 2.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
MFA
Segment breakdown not available.
